Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
3510 results:

  • 1. Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
    Kumbrink J; Demes MC; Jeroch J; Bräuninger A; Hartung K; Gerstenmaier U; Marienfeld R; Hillmer A; Bohn N; Lehning C; Ferch F; Wild P; Gattenlöhner S; Möller P; Klauschen F; Jung A
    Pathol Oncol Res; 2024; 30():1611590. PubMed ID: 38605929
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
    Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
    [No Abstract]    [Full Text] [Related]  

  • 3. Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
    Lv M; Li X; Yin Z; Yang H; Zhou B
    PLoS One; 2024; 19(4):e0294227. PubMed ID: 38564630
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
    Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
    Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Evolutionary trajectories of small cell lung cancer under therapy.
    George J; Maas L; Abedpour N; Cartolano M; Kaiser L; Fischer RN; Scheel AH; Weber JP; Hellmich M; Bosco G; Volz C; Mueller C; Dahmen I; John F; Alves CP; Werr L; Panse JP; Kirschner M; Engel-Riedel W; Jürgens J; Stoelben E; Brockmann M; Grau S; Sebastian M; Stratmann JA; Kern J; Hummel HD; Hegedüs B; Schuler M; Plönes T; Aigner C; Elter T; Toepelt K; Ko YD; Kurz S; Grohé C; Serke M; Höpker K; Hagmeyer L; Doerr F; Hekmath K; Strapatsas J; Kambartel KO; Chakupurakal G; Busch A; Bauernfeind FG; Griesinger F; Luers A; Dirks W; Wiewrodt R; Luecke A; Rodermann E; Diel A; Hagen V; Severin K; Ullrich RT; Reinhardt HC; Quaas A; Bogus M; Courts C; Nürnberg P; Becker K; Achter V; Büttner R; Wolf J; Peifer M; Thomas RK
    Nature; 2024 Mar; 627(8005):880-889. PubMed ID: 38480884
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Metformin and buparlisib synergistically induce apoptosis of non-small lung cancer (NSCLC) cells via Akt/FoxO3a/Puma axis.
    Shanshan W; Hongying M; Jingjing F; Rui Y
    Toxicol In Vitro; 2024 May; 97():105801. PubMed ID: 38479708
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. p53 and Rb Aberrations in small cell lung cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation.
    Papavassiliou KA; Sofianidi AA; Gogou VA; Anagnostopoulos N; Papavassiliou AG
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473726
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
    Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
    Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking.
    Wang M; Li R; Bai M; Zhou X
    Medicine (Baltimore); 2024 Mar; 103(9):e37218. PubMed ID: 38428907
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
    Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
    Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
    Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
    Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
    Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
    Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Next-Generation Sequencing in lung cancers-A Single-Center Experience in Taiwan.
    Lai WA; Huang YS; Chang KC; Yang SF; Yang CJ; Liu YW; Chen HD
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399524
    [No Abstract]    [Full Text] [Related]  

  • 14. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and tp53 mutant undifferentiated lung cancer.
    Chen J; Zheng Q; Wang J; Zhang X; Lv Y
    Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
    Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
    BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype.
    Ma W; Zhou T; Song M; Liu J; Chen G; Zhan J; Ji L; Luo F; Gao X; Li P; Xia X; Huang Y; Zhang L
    J Transl Med; 2024 Feb; 22(1):189. PubMed ID: 38383412
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
    Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
    Yin A; Veerman GDM; van Hasselt JGC; Steendam CMJ; Dubbink HJ; Guchelaar HJ; Friberg LE; Dingemans AC; Mathijssen RHJ; Moes DJAR
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):612-623. PubMed ID: 38375997
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genomic characteristics and immune landscape of super multiple primary lung cancer.
    Yang Z; Zhou B; Guo W; Peng Y; Tian H; Xu J; Wang S; Chen X; Hu B; Liu C; Wang Z; Li C; Gao S; He J
    EBioMedicine; 2024 Mar; 101():105019. PubMed ID: 38364701
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Exosome inhibition improves response to first-line therapy in small cell lung cancer.
    Irep N; Inci K; Tokgun PE; Tokgun O
    J Cell Mol Med; 2024 Feb; 28(4):e18138. PubMed ID: 38353469
    [TBL] [Abstract] [Full Text] [Related]  


    of 176.